Seethalakshmi L, Flores C, Kinkead T, Carboni A A, Malhotra R K, Menon M
Division of Urologic and Transplantation Surgery, University of Massachusetts Medical Center, Worcester 01655.
J Androl. 1992 Jan-Feb;13(1):65-74.
Cis-platinum-based chemotherapy is known to impair spermatogenesis, but the effects of paternal cis-platinum treatment on the progeny are unknown. To study this effect, sexually mature male Sprague-Dawley rats were administered intraperitoneal injections of saline or cis-platinum (0.5 mg/kg per day) for 9 weeks. Every week, one set of control and treated animals was mated with females in proestrus. Nineteen days later, the females were subjected to laparotomy, and the numbers of corpora lutea, resorptions, and normal and abnormal fetuses were noted. In conjunction, the effects of treatment on the hypothalamo-pituitary-gonadal axis of the treated males were evaluated. Cis-platinum-treated animals failed to grow; the weights of the reproductive organs and the sperm counts declined from week 2 onward, and sperm motility was reduced throughout the testing period. Circulating and intratesticular levels of testosterone declined from week 3 of treatment and follicle-stimulating hormone levels were not affected. Serum levels of luteinizing hormone declined from week 3 and were not detectable from week 6 onward. However, the pituitary response to gonadotropin-releasing hormone was intact in all treated groups. There was no significant decrease in fertility, but a prominent increase in pre- and postimplantation losses of fetuses after cis-platinum treatment was observed. There was also a decrease in the male-to-female ratio of the offspring. A small but significant number of malformed and growth-retarded fetuses was also found among the offspring of cis-platinum-treated males. These results suggest that subchronic treatment with low doses of cis-platinum may affect progeny; such effects are seen in addition to the apparent alteration in a number of measures of reproductive function of treated males.
已知顺铂类化疗会损害精子发生,但父本顺铂治疗对后代的影响尚不清楚。为了研究这种影响,对性成熟的雄性Sprague-Dawley大鼠进行腹腔注射生理盐水或顺铂(每天0.5毫克/千克),持续9周。每周将一组对照动物和治疗动物与处于发情前期的雌性动物交配。19天后,对雌性动物进行剖腹手术,记录黄体数、吸收情况以及正常和异常胎儿的数量。同时,评估治疗对接受治疗雄性动物下丘脑-垂体-性腺轴的影响。接受顺铂治疗的动物生长受阻;从第2周起,生殖器官重量和精子计数下降,并且在整个测试期间精子活力降低。从治疗第3周起,睾酮的循环水平和睾丸内水平下降,促卵泡激素水平未受影响。促黄体生成素的血清水平从第3周开始下降,从第6周起无法检测到。然而,所有治疗组中垂体对促性腺激素释放激素的反应均正常。生育能力没有显著下降,但观察到顺铂治疗后胎儿着床前和着床后的损失显著增加。后代的雄雌比例也有所下降。在接受顺铂治疗的雄性动物的后代中还发现了少量但数量可观的畸形和生长发育迟缓的胎儿。这些结果表明,低剂量顺铂的亚慢性治疗可能会影响后代;除了接受治疗的雄性动物生殖功能的多项指标出现明显改变外,还出现了这些影响。